Skip to main content

Table 1 Clinical information and treatment of the two groups

From: The clinical characteristics and risk factors for necrotizing pneumonia caused by Mycoplasma pneumoniae in children

Clinical information and treatmentNP group (n = 37)Control group (n = 74)P value
Clinical presentation (n, %)
 Fever37, 100%74, 100%
 Cough37, 100%74, 100%
 Chest pain3, 8.1%00.035a
 dyspnea4, 10.8%3, 4.1%0.334
Extrapulmonary complications (n, %)
 Elevated liver enzyme level10, 27%28, 37.8%0.258
 Electrolyte disturbance4, 10.8%6, 8.1%0.907
 Hypoproteinemia4, 10.8%2, 2.7%0.182
 Coronary dilatation01, 1.4%1.000a
 Pericardial effusion01, 1.4%1.000a
 Polymorphic erythema01, 1.4%1.000a
Treatment (n, %)
 Administered other antibiotics34, 91.9%51, 68.9%0.007
 Noninvasive ventilation1, 2.7%00.722
 Low molecular weight heparin13, 35.1%42, 58.1%0.032
 Methylprednisolone30, 81.1%65, 87.8%0.339
 Intravenous immunoglobulin10, 27%8, 10.8%0.029
 Fiber bronchoscope examination23, 62.2%48, 64.9%0.780
 Mucous congestion, edema23, 100%48, 100%0.780
 Bronchitis obliterans1, 4.3%00.324a
 Plastic bronchitis1, 4.3%00.324a
  1. a Fisher’s exact test